ANG Lifesciences India Ltd

ANG
Health CarePharmaceuticals
SmallcapWith a market cap of ₹335 cr, stock is ranked 1,464
High RiskStock is 31.41x as volatile as Nifty
322.005.30 (+1.67%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹335 cr, stock is ranked 1,464
High RiskStock is 31.41x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
47.79
PB RatioPB Ratio
8.08
Dividend YieldDiv. Yield
Sector PESector PE
36.39
Sector PBSector PB
4.85
Sector Div YldSctr Div Yld
0.71%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

ANG Lifesciences India is a pharmaceutical company, engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials

Investor PresentationView older 

Oct 26, 2021

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201820192020202176.73121.93127.25154.943.735.666.097.03
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Result 
Announced OnDec 1, 2021

ANG Lifesciences India Ltd - 540694 - Reply Of Email Received From BSE In Regards Of Discrepancies In PDF Of Consolidated Cash Flow Statement For The Half Year Ended As At 30Th September 2021 | Download

ANG Lifesciences India Ltd - 540694 - Reply Of Email Received From BSE In Regards Of Discrepancies In PDF Of Consolidated Cash Flow Statement For The Half Year Ended As At 30Th September 2021 | Download

Cash Dividend 
Ex. DateNov 2, 2021

Interim • Div/Share: ₹ 1

See all events